ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.33
0.14 (6.39%)
▲
5d:
-10.04%
30d:
-29.39%
90d:
+16.5%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ABOS is down 5.1% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 422 OI. Call ratio: 100% View Scanner →
Strength: 7.5/10
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABOS is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABOS is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.33, which is considered oversold relative to its 30-day fair value range of $2.61 to $3.27.
Technical Outlook: Technically, ABOS is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $3.46. The stock is showing strong short-term momentum, up 6.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+237.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABOS is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $3.46. The stock is showing strong short-term momentum, up 6.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+237.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.61 -
$3.27
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.4%)
- BULLISH: Trading 237.9% below Wall St target ($7.40)
- WARNING: Recommendation downgraded due to -10.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.61 -
$3.27
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.25
Resistance Level
$3.46
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.21
Wall Street Target
$7.40
(+237.9%)
Share & Embed Analysis
Last updated: March 31, 2026 10:56 AM ET
Data refreshes hourly during market hours. Next update: 11:56 AM
Data refreshes hourly during market hours. Next update: 11:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Siemers
SELL
895 shares
2026-01-22
Matt Zuga
SELL
1687 shares
2026-01-22
Russell Barton
SELL
462 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
